相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
Zhengbo Song et al.
CLINICAL CANCER RESEARCH (2022)
Experimental HER2-targeted therapies for biliary tract cancer
Alessandro Rizzo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng et al.
CANCER COMMUNICATIONS (2021)
Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study.
Guangjian Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
HER2-targeted therapies - a role beyond breast cancer
Do-Youn Oh et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Egbert F. Smit et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2-Positive Advanced Solid Tumors Excluding Breast Cancer
Yuzhen Yin et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience
Giovanni Brandi et al.
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2020)
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
W. Victoria Lai et al.
EUROPEAN JOURNAL OF CANCER (2019)
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Rafal Dziadziuszko et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K. L. Jhaveri et al.
ANNALS OF ONCOLOGY (2019)
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
Funda Meric-Bernstam et al.
CLINICAL CANCER RESEARCH (2019)
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A multi-histology basket trial of adotrastuzumab emtansine in patients with HER2 amplified cancers.
Bob T. Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
Xin Li et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial
J. Randolph Hecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
M. G. Kris et al.
ANNALS OF ONCOLOGY (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Sharon H. Giordano et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTANA- A Randomized, Phase III Study
Taroh Satoh et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Intragenic ERBB2 kinase mutations in tumours
P Stephens et al.
NATURE (2004)
分享论文
